NEW DELHI (Wednesday, March 25, 2026) — A landmark study published in The Lancet Regional Health Southeast Asia has revealed that antibiotic-resistant typhoid infections are no longer just a medical crisis but a massive economic one for India. In 2023, these resistant strains accounted for 87% of the country’s total disease-related economic burden, which has reached a staggering ₹123 billion ($1.5 billion).
The Economic Crisis for Households
The study, conducted by researchers from the London School of Hygiene and Tropical Medicine (LSHTM) and Christian Medical College (CMC), Vellore, highlights a severe disparity in who pays for treatment.
- Out-of-Pocket Dominance: Households bore a massive 91% of the total expenses.
- Catastrophic Expenditure: Approximately 70,000 families faced “catastrophic” health spending—defined as medical costs exceeding 40% of a household’s non-subsistence income, threatening their ability to afford food or housing.
- Productivity Loss: Beyond direct medical bills, the study estimated a productivity loss of more than ₹4,200 crore due to illness-related absence from work.
Vulnerable Groups and Hotspots
The data shows that the burden is not distributed evenly across the population or geography.
| Category | Finding |
| Most Affected Age | Children under 10 incurred over half of the national economic burden. |
| Primary Resistance | Fluoroquinolone resistance is the main driver, accounting for 82% of all hospitalizations. |
| High-Burden States | Maharashtra, Uttar Pradesh, Andhra Pradesh (incl. Telangana), Tamil Nadu, and West Bengal account for 51% of national costs. |
The “Fluoroquinolone” Factor
Fluoroquinolones were once the “gold standard” for treating severe typhoid because they could reduce fever within four days. However, the study found that 87% of total costs are now linked specifically to fluoroquinolone-resistant infections, which lead to:
- Longer Hospital Stays: Patients stay in wards significantly longer as doctors struggle to find effective alternative drugs.
- Expensive Alternatives: Shift to “third-generation cephalosporins” or azithromycin, which are more costly and often require intravenous administration.
Call for National Vaccination
The authors, including Dr. Vijayalaxmi Mogasale (LSHTM) and Professor Jacob John (CMC Vellore), argue that these findings provide the “missing evidence” needed for policy shifts.
- Typhoid Conjugate Vaccine (TCV): The study strongly supports the immediate introduction of the TCV into India’s Universal Immunisation Programme.
- Targeted Strategy: Given the high burden in specific states like Maharashtra and Delhi, researchers suggest a phased roll-out starting in high-burden metropolitan areas.
- Policy Shift: The findings urge a move toward social health insurance expansion to protect families from falling into poverty due to a preventable infectious disease.
Sources
- The Lancet Regional Health – Southeast Asia: “Economic burden of typhoid fever by antimicrobial resistance in India: a modelling study 2023” (Published March 2026).
- Press Trust of India (PTI): “Antibiotic resistance fuels 87 per cent of India’s typhoid economic burden: Study” (March 25, 2026).
- The Hindu: “Antibiotic resistance fuels 87% of India’s typhoid economic burden” (March 25, 2026).
- LSHTM News: “Typhoid fever costs billions for India’s economy and people” (March 24, 2026).
Leave a Reply